Dalvance (Dalbavancin HCl) Patent Expiration, LOE Window & CMS Spending

Dalvance (Dalbavancin HCl) by AbbVie: FDA Orange Book LOE 2028-05-23, 0 AB generics, $40.8M 2024 CMS Part D & Medicaid spend, and $1,779 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN021883 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-05-23
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.8M
2024 Medicare Part D Spend$17.9M
2024 Medicaid Spend$23.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,779 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.